Insider Selling: Bicara Therapeutics (NASDAQ:BCAX) CEO Sells $284,200.00 in Stock

Bicara Therapeutics Inc. (NASDAQ:BCAX) CEO Claire Mazumdar sold 10,000 shares of the stock in a transaction dated Friday, July 10th. The stock was sold at an average price of $28.42, for a total transaction of $284,200.00. Following the transaction, the chief executive officer directly owned 362,152 shares in the company, valued at $10,292,359.84. This trade represents a 2.69% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Claire Mazumdar also recently made the following trade(s):

• On Monday, April 20th, Claire Mazumdar sold 15,000 shares of Bicara Therapeutics stock. The stock was sold at an average price of $23.61, for a total value of $354,150.00.

Bicara Therapeutics Stock Performance

BCAX stock opened at $27.60 on Friday. The stock’s 50 day simple moving average is $23.83 and its 200 day simple moving average is $20.41. The company has a market cap of $1.81 billion, a P/E ratio of -9.93 and a beta of -0.81. Bicara Therapeutics Inc. has a fifty-two week low of $9.57 and a fifty-two week high of $30.99.

Bicara Therapeutics (NASDAQ:BCAX) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.93) EPS for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.21). Equities analysts predict that Bicara Therapeutics Inc. will post -3.48 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts have commented on the stock. Bank of America began coverage on shares of Bicara Therapeutics in a research note on Wednesday, March 25th. They set a “buy” rating and a $35.00 price target for the company. Wall Street Zen raised shares of Bicara Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Sunday, May 24th. Morgan Stanley lifted their price objective on shares of Bicara Therapeutics from $36.00 to $37.00 and gave the company an “overweight” rating in a report on Tuesday, May 12th. Cantor Fitzgerald reissued an “overweight” rating on shares of Bicara Therapeutics in a research report on Wednesday, May 27th. Finally, Guggenheim assumed coverage on shares of Bicara Therapeutics in a report on Monday, May 11th. They issued a “buy” rating and a $42.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $30.27.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Bicara Therapeutics in the 4th quarter valued at $45,000. Legal & General Group Plc boosted its holdings in Bicara Therapeutics by 64.1% during the 2nd quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock worth $29,000 after acquiring an additional 1,233 shares during the last quarter. Larson Financial Group LLC grew its stake in shares of Bicara Therapeutics by 1,015.5% in the 3rd quarter. Larson Financial Group LLC now owns 3,949 shares of the company’s stock worth $62,000 after acquiring an additional 3,595 shares in the last quarter. Tower Research Capital LLC TRC grew its stake in shares of Bicara Therapeutics by 419.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company’s stock worth $44,000 after acquiring an additional 3,866 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd raised its holdings in shares of Bicara Therapeutics by 385.3% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 5,775 shares of the company’s stock valued at $97,000 after purchasing an additional 4,585 shares during the last quarter.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.